Skip to main content
SpringerLink
Log in

Treatment to Improve Acute Kidney Injury in Cirrhosis

  • Liver (J Bajaj, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Acute kidney injury (AKI) is an ominous complication of decompensated cirrhosis, which can be fatal if not treated promptly. It is important that clinicians recognize that AKI has occurred and institute timely treatment. Recent establishment of diagnostic criteria and treatment guidelines are most useful, and these will be further refined as treatments are being modified to improve patient outcome. To manage such a patient, firstly, the cause of the AKI needs to be identified and any precipitating factors corrected. Bacterial infections are a common cause of AKI in cirrhosis, and it is recommended to offer empirical antibiotics in cases of suspicious bacterial infection until all the cultures are negative. Patients should be given albumin infusion in doses of 1 g/kg of body weight for at least 2 days. This can improve the filling of the central circulation, and also absorb many of the bacterial products or inflammatory cytokines that play a role in mediating the renal dysfunction. Often, albumin infusion alone may be sufficient to reverse the AKI. For patients who have acute or type 1 hepatorenal syndrome (HRS1), which is a special form of AKI, pharmacotherapy in the form of vasoconstrictor will be needed. The vasoconstrictor can be terlipressin, norepinephrine, or midodrine, depending on the local availability of drugs or facilities. Currently, approximately 40 % of patients will respond to a combination of vasoconstrictor and albumin. All patients with HRS1 should be assessed for liver transplant. If accepted for liver transplantation, those patients who do not respond to vasocontrictors and albumin need to be started on renal replacement therapy, which otherwise has no place in the treatment of HRS1. Once listed, liver transplantation should occur promptly, preferable under 2 weeks. Otherwise, the chances for renal recovery after liver transplant are significantly reduced, necessitating a renal transplant at the future date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064–77.

    Article  CAS  PubMed  Google Scholar 

  2. Arroyo V, Gines P, Gerbes A, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–76.

    Article  CAS  PubMed  Google Scholar 

  3. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013;33(1):16–23. This paper outlines the difficulty in coming to an agreement on how to define renal failure in cirrhosis, and lays the ground work for what needs to be done to come to a consensus definition of renal failure, so that we can set criteria for treatments.

    Article  CAS  PubMed  Google Scholar 

  5. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–605.

    Article  CAS  PubMed  Google Scholar 

  6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute dialysis quality initiative workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8(4):R204–12.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.

    Article  PubMed Central  PubMed  Google Scholar 

  8. KDIGO Clinical Practice Guideline for Acute Kidney Injury. AKI definition. Kidney Int. 2012; Suppl 2:19–36.

  9. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60(5):702–9.

    Article  PubMed  Google Scholar 

  10. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131–7.

    Article  PubMed  Google Scholar 

  11. Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013;145(6):1280–9. This paper evaluates the validity of the consensus definition of acute kidney injury in a cohort of infected cirrhotic patients who were admitted into hospital. The authors found that the consensus definition of acute kidney injury accurately predicted the 30-day survival of these patients. This is one of the first papers that confirms that smaller changes in serum creatinine can have a negative impact on the outcome of these patients.

    Article  PubMed  Google Scholar 

  12. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI With mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–62. This paper shows that not only is the diagnosis of acute kidney injury important in determining the prognosis of decompensated cirrhotic patients, progression of the acute kidney injury has an even more negative prognostic implication for these patients.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes AL, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club. Gut. 2015 (in press). This is the most recent effort of the International Ascites Club in trying to bring about a consensus definition and diagnostic criteria of acute kidney injury in cirrhosis, based on a combination of available data and expert opinions. This will set the platform for designing future studies to validate these criteria, and for finding the most appropriate treatment options.

  14. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol. 2012;9(7):382–91.

    Article  CAS  PubMed  Google Scholar 

  15. Mandal AK, Lansing M, Fahmy A. Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis. 1982;2(3):363–74.

    Article  CAS  PubMed  Google Scholar 

  16. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46(6):1872–82.

    Article  PubMed  Google Scholar 

  17. Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2014. Oct 8. A very clear and concise review on the different types of renal failure in cirrhosis.

  18. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012;78(1):1–8.

    PubMed  Google Scholar 

  19. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41(1):3–11. A good review on the most recent pathophysiology on inflammation, and how it relates to acute renal failure. This helps to explain the latest findings that inflammation plays an important role in the development of acute renal failure in cirrhosis.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Montoliu S, Ballesté B, Planas R, Alvarez MA, Rivera M, Miquel M, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol. 2010;8(7):616–22.

    Article  CAS  PubMed  Google Scholar 

  21. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int. 2013;33(3):398–409.

    Article  CAS  PubMed  Google Scholar 

  22. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362(9398):1819–27.

    Article  PubMed  Google Scholar 

  23. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(1):43–51.

    Article  CAS  PubMed  Google Scholar 

  24. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–46.

    Article  CAS  PubMed  Google Scholar 

  25. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396–407. An excellent review on the properties of albumin and its use in the many complications of cirrhosis.

    Article  CAS  PubMed  Google Scholar 

  26. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–96.

    Article  CAS  PubMed  Google Scholar 

  27. Jain L, Sharma BC, Sharma P, Srivastava S, Agrawal A, Sarin SK. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. Dig Liver Dis. 2012;44(12):1027–31.

    Article  CAS  PubMed  Google Scholar 

  28. Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013;59(5):978–83.

    Article  CAS  PubMed  Google Scholar 

  29. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009;50(2):555–64.

    Article  CAS  PubMed  Google Scholar 

  30. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851–60. An interesting study that confirms that the circulating albumin in cirrhosis is abnormal in quantity and function, thereby providing the rationale for the use of albumin in decompensated cirrhosis.

    Article  CAS  PubMed  Google Scholar 

  31. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53(3):830–5.

    Article  CAS  PubMed  Google Scholar 

  32. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352–9.

    Article  PubMed  Google Scholar 

  33. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36(4 Pt 1):941–8.

    Article  CAS  PubMed  Google Scholar 

  34. Garcia-Martinez R, Noiret L, Sen S, Mookerjee R, Jalan R. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury. Liver Int. 2014. doi:10.1111/liv.12528.

    PubMed  Google Scholar 

  35. Garcia-Martinez R, Andreola F, Mehta G, Poulton K, Oria M, Jover M, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol. 2014. Oct 30. (14)00797–1. doi: 10.1016/j.jhep.2014.10.031.

  36. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG, et al. Initial Report of a large, randomized, double blind, placebo-controlled, phase 3 trial of terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (HRS-1): The REVERSE Study. [Abstract] Hepatology. 2014;60(4) Suppl: 255A. This is the latest randomized controlled trial that assesses the use of terlipressin in the management of type 1 hepatorenal syndrome in cirrhosis. It confirms the findings of the 2 previous randomized controlled trials that response to terlipressin improves the overall prognosis of these patients.

  38. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9, CD005162.

    PubMed  Google Scholar 

  39. Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955–61.

    Article  PubMed  Google Scholar 

  40. Israelsen ME, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol. 2014. doi:10.1111/jgh.12709.

    Google Scholar 

  41. Gerbes AL, Huber E, Gülberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137(3):1179.

    Article  PubMed  Google Scholar 

  42. Angeli P, Fasolato S, Cavallin M, Trotta G, Maresio A, Callegaro A, et al. Terlipressin given as continuous intravenous infusion versus terlipressin given as intravenous boluses in the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis. [Abstract]. J Hepatol. 2009;50 Suppl 1:S73.

    Article  Google Scholar 

  43. Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219–26.

    Article  CAS  PubMed  Google Scholar 

  44. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689–97.

    Article  CAS  PubMed  Google Scholar 

  46. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8.

    Article  CAS  PubMed  Google Scholar 

  47. Nassar Junior AP, Farias AQ, D’ Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009;43(7):680–5.

    Article  CAS  PubMed  Google Scholar 

  49. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742–8.

    Article  CAS  PubMed  Google Scholar 

  50. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40(1):55–64.

    Article  CAS  PubMed  Google Scholar 

  51. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7.

    Article  CAS  PubMed  Google Scholar 

  52. Runyon BA. AASLD practice guidelines committee. Management of adult patients with Ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.

    Article  PubMed  Google Scholar 

  53. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol. 2003;38(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  54. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6(3):277–86.

    Article  CAS  PubMed  Google Scholar 

  55. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut. 2010;59(3):381–6.

    Article  CAS  PubMed  Google Scholar 

  56. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59(7):988–1000.

    Article  PubMed  Google Scholar 

  57. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47(2):288–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Rössle M. TIPS: 25 years later. J Hepatol. 2013;59(5):1081–93.

    Article  PubMed  Google Scholar 

  59. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995;122(11):816–22.

    Article  CAS  PubMed  Google Scholar 

  60. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, et al. Hepatorenal syndrome: the 8th international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2012;16(1):R23.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Leithead JA, Hayes PC, Ferguson JW. Advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther. 2014;39(7):699–711.

    Article  CAS  PubMed  Google Scholar 

  62. Marik PE, Wood K, Starzl TE. The course of type 1 hepatorenal syndrome post liver transplantation. Nephrol Dial Transplant. 2006;21(2):478–2.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59(3):361–5.

    Article  CAS  PubMed  Google Scholar 

  64. Wong F, Leung W, Al Beshir M, Marquez M, Renner EL. The outcome of patients with cirrhosis and Type-1 hepatorenal sydrome treated with liver transplantation. Liver Transpl. 2014. doi:10.1002/lt.24049. A retrospective study that assesses the outcome of a homogeneous cohort of patients with type 1 hepatorenal syndrome who underwent liver transplantation. The unexpected finding that dialysis of more than 14 days will separate those patients who will reverse their renal failure with liver transplantation versus those who will not, will stimulate the discussion as to when is the best time to do a liver transplant alone versus combined liver/kidney transplant on these patients.

    Google Scholar 

  65. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17(11):1328–32.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation. 2011;91(10):1141–7.

    Article  CAS  PubMed  Google Scholar 

  67. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med. 1973;289(22):1155–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Cassinello C, Moreno E, Gozalo A, Ortuno B, Cuenca B, Solis-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci. 2003;48(1):179–86.

    Article  CAS  PubMed  Google Scholar 

  69. Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl. 2005;11(9):1048–55.

    Article  PubMed  Google Scholar 

  70. Xu X, Ling Q, Zhang M, Gao F, He Z, You J, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation. 2009;87(10):1514–9.

    Article  PubMed  Google Scholar 

  71. Eason JD, Gonwa TA, Davies CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver–kidney transplantation [SLK]. Am J Transplant. 2008;8(11):2243–51.

    Article  CAS  PubMed  Google Scholar 

  72. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7.

    Article  CAS  PubMed  Google Scholar 

  73. Chok KS, Fung JY, Chan SC, Cheung TT, Sharr WW, Chan AC, et al. Outcomes of living donor liver transplantation in patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012;18(7):1237–44.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Florence Wong has received consultancy fees and grants from Ikaria.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Florence Wong MBBS, MD, FRACP, FRCPC

Authors
  1. Florence Wong MBBS, MD, FRACP, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florence Wong MBBS, MD, FRACP, FRCPC.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, F. Treatment to Improve Acute Kidney Injury in Cirrhosis. Curr Treat Options Gastro 13, 235–248 (2015). https://doi.org/10.1007/s11938-015-0050-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-015-0050-2

Keywords

Search

Navigation